5HT2A Receptor Agonist Compounds With Selective Serotonin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current serotonergic drugs for treating mental illnesses have limited efficacy and cause significant side effects, and psychedelics like psilocybin face regulatory challenges and adverse events, necessitating the development of new compounds with improved selectivity and metabolic stability for serotonin receptor activation.
Innovation Solution
Development of novel compounds with high affinity and selectivity for the 5HT2A serotonin receptor, while minimizing activity at 5HT2B and 5HT2C receptors, and enhanced metabolic stability, potentially offering therapeutic benefits for mental illnesses and CNS disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current serotonergic drugs are used to treat mental illnesses, then they are commercially available and widely used, but they provide limited efficacy and cause significant side effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural modifications at different positions of the serotonin receptor binding site. The compounds feature selective substitution patterns that confer high affinity for 5HT2A receptors while maintaining reduced activity at 5HT2B and 5HT2C receptors, thereby achieving localized optimization of receptor interaction properties to improve efficacy while minimizing side effects
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, positions, and configurations in the compound structure. This includes modifying the indole ring substitutions, alkyl chain lengths, and functional groups to optimize binding affinity and selectivity parameters, resulting in compounds with enhanced therapeutic profiles compared to existing serotonergic drugs
2Reliability
If psychedelics like psilocybin are used to treat mental illnesses, then they show therapeutic potential, but they face regulatory challenges and adverse events
Solution Approach 1:
The patent applies the extraction principle by isolating and optimizing specific molecular features from natural psychedelics like psilocybin. The compounds capture the essential therapeutic properties of psychedelics through selective 5HT2A receptor activation while removing or minimizing the adverse effects associated with non-selective serotonin receptor binding, thereby extracting the beneficial aspects while eliminating the harmful ones
Solution Approach 2:
The patent converts the harmful non-selectivity of psychedelics into a benefit by designing compounds that specifically target 5HT2A receptors. The adverse events caused by off-target binding at 5HT2B and 5HT2C receptors are transformed into selective advantage, where the same receptor binding properties that previously caused side effects are now engineered to produce only therapeutic effects through improved selectivity
3Manufacturing precision
If compounds are designed for high affinity at 5HT2A receptor, then selectivity improves, but metabolic stability may be compromised
Solution Approach 1:
The patent applies segmentation by dividing the compound structure into distinct functional segments: a core indole structure for 5HT2A binding, specific substituent groups for enhancing selectivity, and metabolic stabilizing moieties such as fluorinated alkyl groups or cyclic structures. This segmentation allows independent optimization of each segment's function, maintaining high selectivity while incorporating features that resist metabolic degradation
Solution Approach 2:
The patent employs composite material principles by combining multiple chemical moieties with complementary properties into single hybrid compounds. The compounds integrate pharmacophores for 5HT2A selectivity with metabolic stability enhancers, creating composite molecular structures that exhibit both high receptor selectivity and improved metabolic stability, overcoming the trade-off between these two critical properties
Data Source
AI summary
The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.